Apellis Pharmaceuticals raises $47.1 in Series D financing
Drug developer Apellis Pharmaceuticals Inc raised $47.1 million in Series D preferred stock financing. The round was led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund. Earlier this month Apellis withdrew its plans for an initial public offering, according to an SEC filing.
12 February 2016•3 mins read
